SCHEMBL14756802

SCHEMBL14756802

CNCCNc1ccc(O)c(O)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.53
CYP1A2 P05177 4/20 0.53
HIF1A Q16665 3/20 0.53
HSD17B10 Q99714 3/20 0.53
TSHR P16473 2/20 0.53
MAPK1 P28482 2/20 0.53
TP53 P04637 1/20 0.53
ALOX15 P16050 1/20 0.53
NFKB1 P19838 1/20 0.53
THPO P40225 1/20 0.53
ARG1 P05089 1/20 0.53
KDM4E B2RXH2 3/20 0.52
ALDH1A1 P00352 3/20 0.52
BLM P54132 2/20 0.52
PMP22 Q01453 2/20 0.52
NPSR1 Q6W5P4 2/20 0.52
GMNN O75496 1/20 0.52
LMNA P02545 1/20 0.52
HPGD P15428 1/20 0.52
GFER P55789 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9795817 0.85 TUBB4A (0.47) MAPTCYP1A2HIF1AHSD17B10TSHR
SCHEMBL4060822 0.82 ARG1 (0.55) MAPTCYP1A2HIF1AHSD17B10TSHR
SCHEMBL5547526 0.79 ARG1 (0.57) MAPTCYP1A2HIF1AHSD17B10TSHR
SCHEMBL19145089 0.78 ARG1 (0.52) MAPTCYP1A2HSD17B10MAPK1ARG1
SCHEMBL14756953 0.78 ALDH1A1 (0.58) MAPTHIF1AHSD17B10ARG1KDM4E
SCHEMBL11256391 0.78 ARG1 (0.55) MAPTCYP1A2HIF1AHSD17B10TSHR
SCHEMBL17385598 0.77 ARG1 (0.50) MAPTCYP1A2HIF1AHSD17B10TSHR
SCHEMBL347616 0.77 ARG1 (0.59) MAPTCYP1A2HIF1AHSD17B10TSHR
SCHEMBL22542435 0.77 TMEM97 (0.54) MAPTHIF1AHSD17B10TSHRMAPK1
SCHEMBL29642426 0.77 ARG1 (0.59) MAPTCYP1A2HIF1AHSD17B10TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016115360-A1 C-MYC LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME COFERON, INC. (US) 2016-07-21 WO disclosed
WO-2015081280-A1 BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION COFERON, INC. (US) 2015-06-04 WO disclosed
US-20140243286-A1 BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME COFERON, INC. (US) 2014-08-28 US disclosed
WO-2013033270-A2 BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME COFERON, INC. (US) 2013-03-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243286-A1 BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME BRDT, BRD4, BRD1 MAPT 1845/4885CYP1A2 4875/4885HIF1A 4273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.